ArticleJournal of hepatology2009
Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection.
Article in Journal of hepatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 58 citations in OpenAlex.
- Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients.Journal of hepatology · 2011Trial
- Zika Virus-Induction of the Suppressor of Cytokine Signaling 1/3 Contributes to the Modulation of Viral Replication.Pathogens (Basel, Switzerland) · 2020Article
- Therapeutic strategies for hepatitis B virus infection: towards a cure.Nature reviews. Drug discovery · 2019Review
- The IFN-λ4 Conundrum: When a Good Interferon Goes Bad.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2019Review
- MicroRNA-122 in patients with hepatitis B and hepatitis B virus-associated hepatocellular carcinoma.Journal of gastrointestinal oncology · 2019Review
- Global virus outbreaks: Interferons as 1st responders.Seminars in immunology · 2019Review
- [Relationship between the suppressor of cytokine signaling 3 expression and antiviral efficacy of nucleos(t)ide and interferon alpha therapy for chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019Article
- DHAV-1 Inhibits Type I Interferon Signaling to Assist Viral Adaption by Increasing the Expression of SOCS3.Frontiers in immunology · 2019Article
- Fine-Tuning of Type I Interferon Response by STAT3.Frontiers in immunology · 2019Review
- Effect of branched-chain amino acid supplementation on insulin resistance and quality of life in chronic hepatitis C patients.Biomedical reports · 2018Article
- Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice.The Journal of biological chemistry · 2017Article
- SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?Cellular and molecular life sciences : CMLS · 2016Review
- Host restriction factors for hepatitis C virus.World journal of gastroenterology · 2016Review
- SOCS3 mRNA expression and polymorphisms as pretreatment predictor of response to HCV genotype 3a IFN-based treatment.SpringerPlus · 2016Article
- Dendritic cells: The warriors upfront-turned defunct in chronic hepatitis C infection.World journal of hepatology · 2015Review
- Immune Response in Hepatitis B Virus Infection.Cold Spring Harbor perspectives in medicine · 2015Review
- Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C.Transplantation · 2014Article
- SOCS3, a Major Regulator of Infection and Inflammation.Frontiers in immunology · 2014Review
- The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Article
- Loss and dysregulation of Th17 cells during HIV infection.Clinical & developmental immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
BACKGROUND/
aimsThe response rates of HCV infection to interferon therapy vary depending on viral and host factors. We hypothesized that key regulators of the IFN signaling pathway are predictive of treatment outcome.
methodsWe measured the expression of signal transducer and activator of transcription 1 (STAT1) and suppressor of cytokine signaling 3 (SOCS3) in pretreatment liver biopsies. Staining quantitation was compared to treatment outcomes.
resultsForty-nine patients with HCV and 25 patients with HCV/HIV infection treated with peginterferon/ribavirin were analyzed. Pretreatment hepatic SOCS3 expression was higher in non-responders than responders. Genotype 1 responders had similar levels of SOCS3 as genotype 2/3 responders. African Americans (AA) had higher hepatic SOCS3 than non-AA. Pretreatment hepatic SOCS3 was the most powerful independent predictor of sustained virologic response (SVR), even more so than genotype by logistic regression analysis. Failure to achieve SVR and AA race were independently associated with high hepatic SOCS3 levels. The hepatic expression of STAT-1 did not differ between responders and non-responders.
conclusionsOur data indicate that hepatic SOCS3 is a stronger baseline predictor of antiviral response than viral genotype. Poor response to antiviral therapy in AA may be associated with higher hepatic SOCS3 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.